MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

KalVista Pharmaceuticals Inc

Open

SectorGezondheidszorg

13.01 3.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.47

Max

13.1

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.2M

-49M

EPS

-0.92

Winstmarge

-3,702.322

Werknemers

150

EBITDA

4.4M

-41M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+112.58% upside

Dividenden

By Dow Jones

Volgende Winsten

10 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4.6M

597M

Vorige openingsprijs

9.92

Vorige sluitingsprijs

13.01

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

KalVista Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 nov 2024, 21:11 UTC

Belangrijke Marktbewegers

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Peer Vergelijking

Prijswijziging

KalVista Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

112.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.38 USD  112.58%

Hoogste 39 USD

Laagste 19 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor KalVista Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

11.76 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.